BCWM
CADL icon

Bartlett & Co Wealth Management’s Candel Therapeutics CADL Stock Holding History

Bartlett & Co Wealth Management’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$36.3K Hold
3,520
– – ﹤0.01% 794
2026
Q1 		$26.5K Buy
+3,520
New +$19.2K ﹤0.01% 778

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Bartlett & Co Wealth Management's CADL Position: Q2 2026 in Review

Bartlett & Co Wealth Management held its Candel Therapeutics (CADL) position steady in Q2 2026 at 3,520 shares worth $36.3K. The position accounts for ﹤0.01% of the portfolio, ranked #794.

Bartlett & Co Wealth Management first reported a position in CADL in Q1 2026 and has held it in 2 quarters since. 138 funds tracked by Wall St. Rank hold CADL as of Q2 2026.

  • Bartlett & Co Wealth Management held 3,520 shares of Candel Therapeutics worth $36.3K as of Q2 2026.
  • Bartlett & Co Wealth Management left its Candel Therapeutics share count unchanged in Q2 2026.
  • Candel Therapeutics made up ﹤0.01% of Bartlett & Co Wealth Management's portfolio in Q2 2026, its #794 holding.
  • Bartlett & Co Wealth Management first reported a position in Candel Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 138 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2026.

Based on Bartlett & Co Wealth Management's 13F filing for Q2 2026, filed 24 Jul 2026.